Literature DB >> 32069207

Identifying Patients with Rare Disease Using Electronic Health Record Data: The Kaiser Permanente Southern California Membranous Nephropathy Cohort.

Amy Z Sun1, Yu-Hsiang Shu2, Teresa N Harrison2, Aviv Hever3, Steven J Jacobsen2, Michelle M O'Shaughnessy4, John J Sim1.   

Abstract

INTRODUCTION: Developing a reliable means to identify and study real-world populations of patients with membranous nephropathy (MN) using electronic health records (EHRs) would help advance glomerular disease research. Identifying MN cases using EHRs is limited by the need for manual reviews of biopsy reports.
OBJECTIVE: To evaluate the accuracy of identifying patients with biopsy-proven MN using the EHR in a large, diverse population of an integrated health system.
METHODS: A retrospective cohort study was performed between June 28, 1999, and June 25, 2015, among patients with kidney biopsy results (N = 4723), which were manually reviewed and designated as MN or non-MN. The sensitivity, specificity, and positive predictive value (PPV) of International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes were determined using 2 approaches: 1) clinical (MN-specific codes 581.1, 582.1, or 583.1) and 2) agnostic/data-derived (codes selected from supervised learning at the highest predictive performance).
RESULTS: One year after biopsy, the sensitivity and specificity of an MN diagnosis were 86% and 76%, respectively, but the PPV was 26%. The data-driven approach detected that using only 2 codes (581.1 or 583.1) improved specificity to 94% and PPV to 58%, with a small decrease in sensitivity to 83%. When any code was reported at least 3 times, specificity was 98%; PPV, 78%; and sensitivity, 64%. DISCUSSION: Our findings suggest that ICD-9 diagnosis codes might be a convenient tool to identify patients with MN using EHR and/or administrative claims information. Codes selected from supervised learning achieved better overall performance, suggesting the potential of developing data-driven methods.

Entities:  

Mesh:

Year:  2020        PMID: 32069207      PMCID: PMC7021143          DOI: 10.7812/TPP/19.126

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  14 in total

1.  Identification and validation of lupus nephritis cases using administrative data.

Authors:  L B Chibnik; E M Massarotti; K H Costenbader
Journal:  Lupus       Date:  2010-02-23       Impact factor: 2.911

2.  Validating identification of patients with small vessel vasculitis, with or without renal involvement, using administrative healthcare records.

Authors:  Michelle M O'Shaughnessy; XingXing S Cheng; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  Clin Nephrol       Date:  2017-03       Impact factor: 0.975

3.  Follow-up of Abnormal Estimated GFR Results Within a Large Integrated Health Care Delivery System: A Mixed-Methods Study.

Authors:  Kim N Danforth; Erin E Hahn; Jeffrey M Slezak; Lie Hong Chen; Bonnie H Li; Corrine E Munoz-Plaza; Tiffany Q Luong; Teresa N Harrison; Brian S Mittman; John J Sim; Hardeep Singh; Michael H Kanter
Journal:  Am J Kidney Dis       Date:  2019-07-16       Impact factor: 8.860

4.  Kaiser Permanente Creatinine Safety Program: A Mechanism to Ensure Widespread Detection and Care for Chronic Kidney Disease.

Authors:  John J Sim; Mark P Rutkowski; David C Selevan; Michael Batech; Royann Timmins; Jeff M Slezak; Steven J Jacobsen; Michael H Kanter
Journal:  Am J Med       Date:  2015-06-16       Impact factor: 4.965

5.  End-Stage Renal Disease and Mortality Outcomes Across Different Glomerulonephropathies in a Large Diverse US Population.

Authors:  John J Sim; Simran K Bhandari; Michael Batech; Aviv Hever; Teresa N Harrison; Yu-Hsiang Shu; Dean A Kujubu; Tracy Y Jonelis; Michael H Kanter; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2018-01-24       Impact factor: 7.616

6.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

7.  Glomerular Diseases: Registries and Clinical Trials.

Authors:  Marva M Moxey-Mims; Michael F Flessner; Lawrence Holzman; Frederick Kaskel; John R Sedor; William E Smoyer; Aliza M Thompson; Lynne Yao
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-26       Impact factor: 8.237

8.  The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis.

Authors:  James B Wetmore; Haifeng Guo; Jiannong Liu; Allan J Collins; David T Gilbertson
Journal:  Kidney Int       Date:  2016-07-15       Impact factor: 10.612

9.  Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey.

Authors:  Michelle M O'Shaughnessy; Susan L Hogan; Bawana D Thompson; Rosanna Coppo; Agnes B Fogo; J Charles Jennette
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992

10.  Low Systolic Blood Pressure From Treatment and Association With Serious Falls/Syncope.

Authors:  John J Sim; Hui Zhou; Simran Bhandari; Rong Wei; Jeff W Brettler; Jocelyn Tran-Nguyen; Joel Handler; Daichi Shimbo; Steven J Jacobsen; Kristi Reynolds
Journal:  Am J Prev Med       Date:  2018-08-23       Impact factor: 5.043

View more
  6 in total

1.  Autosomal Dominant Polycystic Kidney Disease Prevalence among a Racially Diverse United States Population, 2002 through 2018.

Authors:  Thet T Aung; Simran K Bhandari; Qiaoling Chen; Fatima T Malik; Cynthia J Willey; Kristi Reynolds; Steven J Jacobsen; John J Sim
Journal:  Kidney360       Date:  2021-09-22

2.  Optimizing the Electronic Health Record for Clinical Research: Has the Time Come?

Authors:  Michelle N Rheault
Journal:  Kidney360       Date:  2021-12-30

3.  Big Data and Glomerular Disease: Uncovering Common Outcomes of Rare Disease.

Authors:  Dorey A Glenn; Susan L Hogan
Journal:  J Am Soc Nephrol       Date:  2021-09       Impact factor: 14.978

4.  Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018.

Authors:  Svenja Ney; Peter Ihle; Thomas Ruhnke; Christian Günster; Guido Michels; Katharina Seuthe; Martin Hellmich; Roman Pfister
Journal:  Clin Res Cardiol       Date:  2022-10-14       Impact factor: 6.138

5.  Enhanced rare disease mapping for phenome-wide genetic association in the UK Biobank.

Authors:  Matthew T Patrick; Redina Bardhi; Wei Zhou; James T Elder; Johann E Gudjonsson; Lam C Tsoi
Journal:  Genome Med       Date:  2022-08-09       Impact factor: 15.266

6.  Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study.

Authors:  Alan S Go; Thida C Tan; Glenn M Chertow; Juan D Ordonez; Dongjie Fan; David Law; Leonid Yankulin; Janet M Wojcicki; Sijie Zheng; Kenneth K Chen; Farzien Khoshniat-Rad; Jingrong Yang; Rishi V Parikh
Journal:  J Am Soc Nephrol       Date:  2021-06-18       Impact factor: 14.978

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.